Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Finished Goods (2022 - 2026)

Axsome Therapeutics' Finished Goods history spans 5 years, with the latest figure at $15.9 million for Q1 2026.

  • On a quarterly basis, Finished Goods rose 77.28% to $15.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.9 million, a 77.28% increase, with the full-year FY2025 number at $11.3 million, up 25.53% from a year prior.
  • Finished Goods hit $15.9 million in Q1 2026 for Axsome Therapeutics, up from $11.3 million in the prior quarter.
  • Over the last five years, Finished Goods for AXSM hit a ceiling of $15.9 million in Q1 2026 and a floor of $1.6 million in Q4 2022.
  • Historically, Finished Goods has averaged $8.7 million across 5 years, with a median of $9.0 million in 2025.
  • Biggest five-year swings in Finished Goods: skyrocketed 506.48% in 2023 and later decreased 12.0% in 2025.
  • Tracing AXSM's Finished Goods over 5 years: stood at $1.6 million in 2022, then skyrocketed by 506.48% to $9.6 million in 2023, then decreased by 6.81% to $9.0 million in 2024, then increased by 25.53% to $11.3 million in 2025, then skyrocketed by 40.85% to $15.9 million in 2026.
  • Business Quant data shows Finished Goods for AXSM at $15.9 million in Q1 2026, $11.3 million in Q4 2025, and $10.3 million in Q3 2025.